Synonym
Butantrone; CCRIS2041; CCRIS-2041; CCRIS 2041
IUPAC/Chemical Name
9(10H)-Anthracenone, 1,8-dihydroxy-10-(1-oxobutyl)-
InChi Key
AHZXFRRDQXXPJD-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H16O4/c1-2-5-12(19)15-10-6-3-8-13(20)16(10)18(22)17-11(15)7-4-9-14(17)21/h3-4,6-9,15,20-21H,2,5H2,1H3
SMILES Code
O=C1C2=C(C=CC=C2O)C(C(CCC)=O)C3=CC=CC(O)=C13
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Butantrone is the 10-butyryl derivative of dithranol with antipsoriatic activity.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
296.32
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Männistö PT, Hanhijärvi H, Kosma VM, Collan Y. A 6-month dermal toxicity test with dithranol and butantrone in miniature swine. Contact Dermatitis. 1986 Jul;15(1):1-9. doi: 10.1111/j.1600-0536.1986.tb01253.x. PMID: 2944694.
2: Göransson A. Comparison of dithranol and butantrone in short contact therapy of psoriasis. Acta Derm Venereol. 1987;67(2):149-53. PMID: 2438880.
3: Hanhijärvi H, Nevalainen T, Männistö P. A six month dermal irritation test with anthralins in the Göttingen miniature swine. Arch Toxicol Suppl. 1985;8:463-8. doi: 10.1007/978-3-642-69928-3_107. PMID: 3913406.
4: Remitz A, Kariniemi AL, Lehtonen E, Nordling S. Inhibition of proliferation of HeLa cells by dithranol (anthralin) and 1o-butyryl dithranol (butantrone). Br J Dermatol. 1989 Apr;120(4):525-31. doi: 10.1111/j.1365-2133.1989.tb01326.x. PMID: 2730843.
5: Brandt H. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). II. Clinical comparison of dithranol and butantrone sticks with special reference to side effects. Acta Derm Venereol. 1987;67(1):55-61. PMID: 2436415.
6: Remitz A. Short-contact therapy for psoriasis with 3.9% butantrone (10-butyryl dithranol). Acta Derm Venereol. 1989;69(4):351-4. PMID: 2568062.
7: Müller K, Gürster D. Hydroxyl radical damage to DNA sugar and model membranes induced by anthralin (dithranol). Biochem Pharmacol. 1993 Nov 17;46(10):1695-704. doi: 10.1016/0006-2952(93)90573-f. PMID: 8250955.
8: Viluksela M, Debets FM, van der Hoeven JC, Männistö PT. Dithranol (anthralin) and 10-butyryl dithranol (butantrone) do not morphologically transform cultured C3H 10T1/2 C18 mouse embryo fibroblasts. Acta Derm Venereol. 1994 Jan;74(1):54-6. doi: 10.2340/00015555745456. PMID: 7908485.
9: Göransson A. Irritation and staining by dithranol (anthralin) and butantrone (10-butyryl dithranol): further short contact and tape stripping experiments. Acta Derm Venereol. 1987;67(1):72-6. PMID: 2436419.
10: Viluksela M, Haasio K, Männistö PT. Studies on the contact sensitizing activity of dithranol (anthralin) and 10-butyryl dithranol (butantrone). Contact Dermatitis. 1990 Aug;23(2):103-10. doi: 10.1111/j.1600-0536.1990.tb03231.x. PMID: 2209005.
11: Männistö PT, Kirkland D, Viluksela M, Tikkanen L. Toxicological studies with dithranol and its 10-acyl analogues. Arch Toxicol. 1986 Oct;59(3):180-5. doi: 10.1007/BF00316330. PMID: 3813885.
12: Greaves MW. Irritation and staining by 10-butyryl dithranol (butantrone) in psoriasis. Int J Clin Pharmacol Res. 1986;6(4):315-6. PMID: 2428761.
13: Laakso S, Römer L, Mustakallio KK. Inhibition of soybean lipoxygenase-1 by 10-butyryl substituted 1,8-dihydroxy-9-anthrone (butantrone). Med Biol. 1986;64(1):43-5. PMID: 3088340.
14: Viluksela M, Puotunen E, Newman AJ, Männistö PT. Tumor-producing and skin- irritating activity of dithranol (anthralin) and its 10-acyl analogues in SENCAR mice. Carcinogenesis. 1986 Oct;7(10):1755-60. doi: 10.1093/carcin/7.10.1755. PMID: 3757176.
15: Göransson AM, Kolari PJ, Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds. V. Short-contact and tape-stripping experiments with dithranol and butantrone. Acta Derm Venereol. 1984;64(2):134-9. PMID: 6203301.
16: Mustakallio KK, Brandt H. Antipsoriatic activity of 10-acyl analogues of dithranol (anthralin). I. Phase I clinical trial of 10-propionyl dithranol and 10-butyryl dithranol (butantrone). Acta Derm Venereol. 1984;64(1):63-6. PMID: 6203285.
17: Männistö PT, Vaissi L, Mustakallio KK, Viluksela M, Kosma VM, Collan Y. Tumor-producing activity of dithranol (anthralin) and two of its 10-acyl analogs in the dorsal skin of female NMRI mice. J Pharmacol Exp Ther. 1984 Apr;229(1):255-60. PMID: 6423812.
18: Männistö P, Havas A, Haasio K, Hanhijärvi H, Mustakallio K. Skin irritation by dithranol (anthralin) and its 10-acyl analogues in 3 animal models. Contact Dermatitis. 1984 Mar;10(3):140-5. doi: 10.1111/j.1600-0536.1984.tb00019.x. PMID: 6232099.
19: Rao K, Ch B, Narasu LM, Giri A. Antibacterial activity of Alpinia galanga (L) Willd crude extracts. Appl Biochem Biotechnol. 2010 Oct;162(3):871-84. doi: 10.1007/s12010-009-8900-9. Epub 2010 Apr 13. PMID: 20387130.
20: Mustakallio KK, Kolari PJ. Irritation and staining by dithranol (anthralin) and related compounds. IV. Visual estimation of erythema compared with contact thermometry and laser Doppler flowmetry. Acta Derm Venereol. 1983;63(6):513-8. PMID: 6198841.
